arrow
P

Pierre Nahon

liver unit
H指数:58
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data

一项多中心国家II期临床试验,评估Tislelizumab单药治疗Child-Pugh B级和ALBI 1级或2级肝功能评分的肝细胞癌患者的疗效:UCGI 41 HESTIA试验设计与初步安全性数据

2025-08-050
PRE
Improving risk stratification and detection of early HCC using ultrasound-based deep learning models

基于超声的深度学习模型改善肝细胞癌的风险分层和早期检测

2025-07-010
OAAI
The role of early MRI in assessing the risk of local tumor progression following irreversible electroporation for hepatocellular carcinoma treatment

早期MRI在评估不可逆电穿孔治疗肝细胞癌后局部肿瘤进展风险中的作用

2025-05-280
OA
Insulin-like Growth Factor-1 Reflects Liver Disease Stage and Improves Prediction of Liver-related Mortality

胰岛素样生长因子-1反映肝脏疾病分期并改善肝相关死亡预测

2025-05-140
OAAI
Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma

经皮射频消融治疗肝细胞癌期间肿瘤和非肿瘤活检的应用价值

2025-04-220
OAAI
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis

非侵入性检测动态在指导肝硬化患者HCV治愈后HCC监测决策中的价值

2025-02-260
PRE
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study
2024-11-010
OAAI
A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry
2024-06-017
OAAI